Aug 5, 2026 earnings call — Earnings beat and raised full-year outlook
CVS reported Q2 revenue of over $106 billion and raised full-year adjusted EPS guidance to $7.90 to $8.10.
Revenue $106.1B (est $100.0B) · EPS $2.58 (est $1.87)
Key quotes
"As demand for these therapies continue to grow, consumers are increasingly focused on 3 things: affordability, access and convenience. CVS Health is a leader in all 3."
"Last month, we began the targeted launch of our Health100 platform, including Haio, our new AI-powered assistant."
"So far this year, we've delivered more than $2 billion of year-over-year improvement in adjusted operating income, reflecting both our commitment to restoring this business to its full potential and the consistency of execution behind it."
Analyst Q&A 7
340B headwinds and specialty offsets
Q (Michael Cherny · Leerink Partners): The analyst asked how CVS will manage HSS growth in 2027, specifically whether formulary conversions or specialty pharmacy actions can offset 340B headwinds and what the pathway is to mitigate 340B given policy uncertainty.
A: Management said they remain confident in enterprise earnings growth and see multiple ways to hit targets. They acknowledged 340B pressure and a more normal selling season, and highlighted specialty pharmacy, specialty generics, and innovations like Cordavis as ways to create savings and value for customers.
"And secondly, we continue to create innovative solutions like Cordavis, where we launched a biosimilar, and that's generated over $1.8 billion of savings on just Humira for our customers." — Prem Shah
Medicare Advantage and GLP-1s
Q (Lisa Gill · JPMorgan): The analyst asked about underlying trends in Health Benefits, how CVS will bid for Medicare Advantage and Medicare Part D in 2027, and whether GLP-1s can be meaningful growth over time.
A: Management said Aetna is performing well across Medicaid, commercial, and Medicare, with Medicare ahead of expectations and disciplined bidding for 2027 to return to target margins. They said Part D is performing in line with expectations after derisking actions. On GLP-1s, they said these are funded for many customers and CVS can manage costs in funded programs while also serving cash markets through MinuteClinic and manufacturer partnerships.
"As I think about '27, as we contemplated the bids, we're taking that same focus to return the business to target margins and the same discipline." — Steven Nelson
Share buybacks and retail strength durability
Q (Justin Lake · Wolfe): The analyst asked whether the $8.44 floor for 2027 assumes share repurchase or other capital deployment, and whether retail script and PCW growth is sustainable as Rite Aid tailwinds normalize and cost-plus rollout stabilizes gross margins.
A: Management said the 2027 plan only assumes offsetting dilution, with nothing additional assumed today. They described retail strength as the result of fixing store service, empowering pharmacists, cost-based pricing (CostVantage), industry-leading cost of goods, and continued investments driving script growth and front-store sales above market.
"Similar to what we talked about at Investor Day, we are only assuming offsetting dilution in '27, Justin." — Brian Newman (CFO)
Commercial margins and No Surprises Act impact
Q (Stephen Baxter · Wells Fargo): The analyst asked for an update on commercial risk business margins versus long-term targets and how the No Surprises Act IDR process is affecting cost trend and margins this year versus last year.
A: Management said the commercial business is performing in line with expectations, with disciplined pricing and growth across fully insured and self-insured markets. They said IDR is a component of trend they have accounted for, they are working upstream with providers to address disputes, and that the dispute process is being abused by some and needs regulatory work to fix.
"When we do have a dispute, we're resolving it more quickly and appropriately." — Steven Nelson
Technology and AI investments and impact
Q (Erin Wilson Wright · Morgan Stanley): The analyst asked about timing and magnitude of technology and AI investments, their cadence into 2027, and how AI will create cost savings and revenue opportunities near- and medium-term.
A: Management said they view AI and technology as central to becoming a consumer-based health care technology business and will invest responsibly, anchored in human touch and privacy. They described AI uses across claims, colleague tools, member experience, and provider work, and said prior investments and technology efficiencies have generated over $1 billion in OpEx savings.
"Over the last few years, as David said, we've generated actually some significant savings over $1 billion in OpEx savings reductions." — Brian Newman (CFO)
What is driving new 340B pressure
Q (Andrew Mok · Barclays): The analyst asked what is causing the incremental 340B pressure now (claims penetration, manufacturer contracting, reimbursement) and what within HSS will offset the headwind this year.
A: Management said manufacturers are imposing restrictions on covered entities, which led to the second quarter impact, and that large specialty drugs becoming generic also creates pressure. They said they fully offset the Q2 impact through broader Caremark performance and are working with covered entities to navigate the program, but they did not size the 340B headwind and will give more detail later in the year.
"Pharma manufacturers are imposing restrictions on covered entities that led to some of the impact that we're seeing in the second quarter." — Prem Shah
Pulled-forward value creation and timing
Q (Elizabeth Anderson · Evercore): The analyst asked what operational actions were pulled forward in H1, whether that gives room to do more in H2, and whether those are one-time or ongoing opportunities into 2027.
A: Management said they continue to invest in capabilities, technology, and colleagues and are seeing results across segments, including corporate. They said investments are deliberate, tracked for return, and captured in the full year beat-and-raise and in the modeled 2027 floor, so further opportunities will be evaluated as part of disciplined capital management.
"We had some investments in capabilities and technology, and that continues." — Brian Newman (CFO)